海辰药业(300584) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 was CNY 136,619,605.45, a decrease of 20.62% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 7,097,146.26, down 40.13% year-on-year[3] - Basic earnings per share decreased by 40.18% to CNY 0.0591[3] - Total operating revenue for Q3 2021 was CNY 453.52 million, a decrease of 17.2% compared to CNY 547.95 million in the same period last year[19] - Net profit for Q3 2021 was CNY 27.53 million, a decline of 42.4% from CNY 47.79 million in Q3 2020[20] - Basic and diluted earnings per share for Q3 2021 were CNY 0.2353, compared to CNY 0.4028 in the same quarter last year[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 966,706,197.11, an increase of 6.64% from the end of the previous year[3] - The company's total assets as of September 30, 2021, amount to 966,706,197.11 yuan, an increase from 906,518,927.96 yuan at the end of 2020[16] - The total current assets are reported at 296,034,699.87 yuan, slightly up from 293,742,731.79 yuan[16] - The company's total liabilities as of Q3 2021 were CNY 275.43 million, an increase from CNY 227.55 million year-over-year[18] - The total liabilities stood at ¥227,547,335.52, remaining consistent with the previous year[28] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 31,877,489.49, down 26.11%[3] - Cash inflow from operating activities was CNY 485.23 million, compared to CNY 547.50 million in the previous year[23] - The net cash flow from operating activities for Q3 2021 was ¥31,877,489.49, a decrease of 26.1% compared to ¥43,144,565.78 in Q3 2020[24] - The total cash outflow from investing activities was ¥111,478,073.45, down 24.5% from ¥147,728,102.80 in the same period last year[24] - The net cash flow from financing activities increased to ¥27,601,882.78, compared to ¥10,666,510.01 in Q3 2020, representing a growth of 158.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,705[11] - The largest shareholder, Cao Yuping, holds 42.08% of shares, totaling 50,491,306 shares, with 37,868,479 shares pledged[11] - The second-largest shareholder, Jiang Xiaoqin, holds 9.98% of shares, totaling 11,973,913 shares[11] Operating Costs and Expenses - The company experienced a 40.26% decrease in operating costs, totaling CNY 81,895,178.55, primarily due to a decline in revenue from a subsidiary[9] - Total operating costs for Q3 2021 were CNY 423.36 million, down 14.6% from CNY 495.57 million year-over-year[19] - Research and development expenses for Q3 2021 amounted to CNY 18.61 million, a decrease of 21.5% from CNY 23.72 million in the same period last year[19] Other Financial Metrics - Investment income decreased by 55.66% to CNY -100,487.40, attributed to acceptance discounting[9] - The company reported a foreign exchange gain of CNY 268.35 thousand in Q3 2021, compared to a gain of CNY 245.04 thousand in the same period last year[20] - The company has a total of 55,954,749 shares under lock-up agreements, primarily due to executive lock-up[13] - The company's cash and cash equivalents decreased to 91,089,838.96 yuan from 103,225,547.36 yuan[15] - Short-term borrowings increased to 100,087,090.38 yuan from 70,075,277.77 yuan[16] - The total non-current assets are reported at 670,671,497.24 yuan, up from 612,776,196.17 yuan[16] Accounting Changes - The company implemented a new leasing standard starting from 2021, which required adjustments to the financial statements[29]